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Human Gingival Mesenchymal Stem Cells (hGMSCs) are multipotential cells that can
expand and differentiate in culture under specific and standardized conditions. In the
present study, we have investigated whether in vitro pre-treatment of hGMSCs with
Cannabidiol (CBD) can influence their expression profile, improving the therapeutic
potential of this cell culture. Following CBD treatment (5µM) for 24 h, gene expression
analysis through Next Generation Sequencing (NGS) has revealed several genes
differentially expressed between CBD-treated hGMSCs (CBD-hGMSCs) and control
cells (CTR-hGMSCs) that were linked to inflammation and apoptosis. In particular, we
have demonstrated that CBD treatment in hGMSCs prevented the activation of the
NALP3-inflammasome pathway by suppressing the levels of NALP3, CASP1, and IL18,
and in parallel, inhibited apoptosis, as demonstrated by the suppression of Bax. CBD
treatment was also able to modulate the expression of the well-known mesenchymal
stem cell markers (CD13, CD29, CD73, CD44, CD90, and CD166), and other surface
antigens. Specifically, CBD led to the downregulation of genes codifying for antigens
involved in the activation of the immune system (CD109, CD151, CD40, CD46, CD59,
CD68, CD81, CD82, CD99), while it led to the upregulation of those implicated in the
inhibition of the immune responses (CD47, CD55, CD276). In conclusion, the present
study will provide a new simple and reproducible method for preconditioning hGMSCs
with CBD, before transplantation, as an interesting strategy for improving the hGMSCs
molecular phenotype, reducing the risk of immune or inflammatory reactions in the host,
and in parallel, for increasing their survival and thus, their long-term therapeutic efficacy.
Keywords: cannabidiol, human gingival mesenchymal stem cells, immunophenotype, next generation sequencing,
inflammasome
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INTRODUCTION
During the last decades, Mesenchymal Stem Cells (MSCs) have
attracted much attention for their ability to transdifferentiate
into several tissues, under specific conditions, and therefore, to
potentially reconstitute the damaged organs and tissues (Zhang
et al., 2009; Patel et al., 2013). They have already been isolated
from different tissues, including bone marrow, adipose tissue,
umbilical cord blood and oral cavity (Hass et al., 2011). In 2006,
The International Society for Cellular Therapy has established
the minimal criteria for defining MSCs: they must be plastic-
adherent in standard culture conditions, they must express
specific surface antigens like the cluster of differentiation (CD)
CD105, CD73, and CD90 in flow cytometry, and they must
lack expression of CD45, CD34, CD14, or CD11b, CD79a, or
CD19 and HLA class II (Dominici et al., 2006). Moreover,
they must show a multipotent ability to differentiate into
several mesenchymal lineages such as osteoblasts, adipocytes and
chondroblasts under standard in vitro differentiating conditions
(Dominici et al., 2006).
In a recent work, our group has demonstrated the beneficial
effect of the human periodontal ligament stem cells, an
oral-derived MSC lineage, in experimental autoimmune
encephalomyelitis models (Trubiani et al., 2016a). Among oral-
derived MSCs, the human Gingival Mesenchymal Stem Cells
(hGMSCs) have been recently explored since they have shared
many common features to other MSCs such as a spindle-like
cell morphology, plastic adherence, the expression profile of
specific cell surface markers, multipotent differentiation, and
even immunomodulatory functions (Xiao and Nasu, 2014; Jin
et al., 2015; Fawzy El-Sayed and Dörfer, 2016). One of the
major advantage of hGMSCs compared to MSCs isolated from
other tissue, is their abundance and easy isolation from gingiva
through a minimally invasive dental procedure (Du et al.,
2016; Fawzy El-Sayed and Dörfer, 2016). Therefore, following
expansion and pre-differentiation into a desired tissue type,
hGMSCs potentially could be re-implanted for tissue repair in
the patients.
Despite the therapeutic potential of MSCs in stem cell-
based therapies, certain issues need to be addressed, such as
the risk of immune rejection which can affect MSCs survival
and thus their long-term fate once transplanted in vivo.
Current approaches to prevent immune rejections are based
on immunosuppressive drugs which induce an immunological
tolerance in the host. However, the prolonged use of these
therapies has been associated with increased risk to develop other
pathological conditions, such as diabetes, hypertension, and
nephrotoxicity (Merville, 2005). As a consequence, new strategies
that prevent immune rejections affecting stem cell survival in
vivo and that assure a successful long-term engraftment, are
needed. Here, we propose an alternative strategy to overcome
these issues which consists in preconditioning hGMSCs in vitro
with a cannabinoid compound, the Cannabidiol (CBD). Thus
far, scientists have found that cannabinoids by interacting with
several receptors, including the endocannabinoid receptors type
1 and type 2 (CB1R and CB2R), can modulate several pathways,
such as stem cells self-renewal, proliferation and differentiation
(Galve-Roperh et al., 2013). Therefore, it is not surprising that
many studies are aimed at evaluating the therapeutic potential
of different exogenous cannabinoids, among which CBD has
received much attention since it is devoid of psychotropic effects
compared to other cannabinoids.
In this study, we have performed a Next Generation
Sequencing (NGS)-based gene expression profiling in order to
evaluate whether CBD treatment can modify the molecular
phenotype of hGMSCs, enhancing their therapeutic efficacy.
MATERIALS AND METHODS
Extraction and Isolation of CBD
Pure CBD (>99%) was isolated from Carmagnola, an Italian
variety of industrial C. sativa and obtained from greenhouse
cultivation at CREA-CIN, Rovigo (Italy), according to a
standardized method of the cannabinoid purification reported
by Taglialatela-Scafati et al. (2010), in order to avoid any
trace of THC that could interfere in the trial or cause legal
limitation. The isolation and purification of cannabinoids were
done in accordance with Italian legal status (Authorization
SP/106 23/05/2013 of the Ministry of Health, Rome, Italy).
Isolation and Immunophenotyping of
hGMSCs
hGMSCs Culture Establishment
Gingival tissue biopsies were obtained from five healthy
adult volunteers with no gingival inflammation. The gingival
specimens were completely de-epithelialized with a scalpel, for
the exclusion of the most of the keratinocytes resident in
the gingival. In brief, the connective tissues were grinded and
then washed several time with PBS (LiStarFish, Milan, Italy)
and subsequently cultured using TheraPEAKTMMSCGM-CDTM
BulletKit serum free, chemically defined (MSCGM-CD) medium
for the growth of human MSCs (Lonza, Basel, Switzerland). The
medium was changed twice a week, and cells spontaneously
migrating from the explant fragments after reaching about 80%
of confluence, were trypsinized using Triple Select (LiStar Fish)
(Diomede et al., 2014). On day 6, colonies of 50 or more cells
were scored as colony-forming unit fibroblasts (CFU).
Cytofluorimetric Evaluation
Samples were stained for surface or intracellular antigens, as
previously described (Cianci et al., 2016). For surface staining,
samples were resuspended in 100µl washing buffer (0.1% sodium
azide and 0.5% bovine serum albumine in PBS) containing
the appropriate amount of surface antibodies; samples were
incubated for 30 min at 4◦C in the dark. Cells were washed
(3 ml of washing buffer), centrifuged (4◦C, 400 X g, 8 min),
resuspended with 1ml PBS 0.5% paraformaldehyde, incubated
for 5 min at RT, washed, centrifuged (4◦C, 400 X g, 8min) and
stored at 4◦C in the dark until their acquisition. For intracellular
staining, cells were resuspended in 1 ml of FACS Lysing solution
(BD), vortexed and incubated at room temperature (RT) in the
dark for 10 min. Samples were centrifuged (4◦C, 400 X g, 8 min);
1 ml of Perm 2 (BD) was added to each tube and cells were
incubated at RT in the dark for 10 min. Samples were washed
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and centrifuged (4◦C, 400 X g, 8 min). Cells were resuspended
in 100 µl of washing buffer containing the appropriate amount
of intracellular antibodies and incubated for 30 min at 4◦C
in the dark. Cells were centrifuged (4◦C, 400 X g, 8 min),
resuspended with 1 ml PBS 0.5 % paraformaldehyde for 5 min
at RT, washed, centrifuged (4◦C, 400 X g, 8 min) and stored at
4◦C in the dark until the acquisition. Cells were analyzed on a
FACS Calibur flow cytometer (BD), using CellQuestTM software
(BD). Quality control included regular check-ups with Rainbow
Calibration Particles (BD Biosciences). Debris was excluded from
the analysis by gating on morphological parameters; 20,000 non-
debris events in the morphological gate were recorded for each
sample. To assess non-specific fluorescence we used isotype
controls. All antibodies were titrated under assay conditions
and optimal photomultiplier voltages (PMT) were established
for each channel. Data were analyzed using FlowJoTM software
(TreeStar, Ashland, OR). Mean Fluorescence Intensity Ratio
(MFI Ratio) was calculated dividing the MFI of positive events
by the MFI of negative events (Trubiani et al., 2016b).
Multipotent Differentiation of hGMSCs
Osteogenic differentiation
7.5 × 103 cells /cm2 CTR-hGMSCs and CBD-hGMSCs,
were seeded at 2nd passage in a 6-well cell culture plate
(Falcon) and incubated overnight at 37◦C, in a humidified
5% CO2 atmosphere. The culture medium was replaced with
osteogenic induction medium represented of MSCGM-CD
medium supplemented with 100 nM dexamethasone (Applichem
GmbH, Darmstadt, Germany), 10 nM β-glycerol-phosphate
(Applichem) and 0.05 mM 2-phosphate-ascorbic acid (Sigma-
Aldrich). The medium was replaced every 3 days. At days 21
Alizarin Red S staining (Sigma-Aldrich Co.) was performed to
detect calcium formation (Trubiani et al., 2015).
Adipogenic differentiation
CTR-hGMSCs and CBD-hGMSCs were seeded in a 6-well
cell culture plate (Falcon) at a density of 2 7.5 × 103 cells
/cm2 and incubated overnight. The medium was replaced with
adipogenic induction medium (Lonza) composed by induction
and maintenance medium. The medium After 28 days of
treatment samples were fixed and stained withOil RedOworking
solution (Sigma-Aldrich) and counterstained with hematoxylin
to detect the oil globules. Images were collected using light
microscopy Leica DMIL (Leica Microsystem, Milan, Italy)
(Trubiani et al., 2016b).
Cell Culture Conditions and Drug
Treatment
hGMSCs were cultured in monolayer using DMEM high-glucose
medium (CARLO ERBA, Italy) containing 10% fetal bovine
serum (FBS) (Sigma-Aldrich Co. Ltd., USA). The cells were
grown in logarithmic phase at 37◦C in a moisturized atmosphere
of 5% CO2 and 95% air. For drug treatment, cells at passage 10
were grown until 70–80% confluence and then, they were treated
with CBD (5 µM) for 24 h (CBD-hGMSCs). Untreated cells were
used as control (CTR-hGMSCs) and cells treated with vehicle
(0.1%DMSO) were also included as a control (DMSO-hGMSCs).
For antagonists study, cells were incubated for 2 h with different
combinations of SR141716A (CB1R antagonist; 1µM) or AM630
(CB2R antagonist;100 nM) before CBD administration for 24 h.
All antagonists were purchased from Tocris Bioscience, UK. All
the experiments were made in triplicates and repeated for three
independent times.
Preparation of RNA Libraries for Deep
Sequencing
Total RNA was isolated with a Reliaprep RNA Cell Miniprep
System (Promega, Milano, Italy). RNA sequencing libraries were
prepared using TruSeq RNA Access library kit (Illumina, Inc.,
San Diego, CA, USA) according to the manufacturer’s protocol.
Thereafter, RNA samples (50 ng) were fragmented at 94◦C for
8 min on a thermal cycler. First strand cDNA syntheses were
performed at 25◦C for 10 min, 42◦C for 15 min, and 70◦C
for 15 min, using random hexameres and the SuperScript II
Reverse Transcriptase (Invitrogen, Milan, Italy). In a second
strand cDNA synthesis, the RNA templates were removed and
a second replacement strand was generated by incorporation
dUTP (in place of dTTP, to keep strand information) to
generate double strands cDNA. The AMPure XP beads (Beckman
Coulter) were used to clean up the blunt-ended cDNA from
the second strand reaction mix. The 3′ends of the cDNA were
then adenylated to facilitate the adaptor ligation in the next
step. After ligation of indexing adaptors, the AMPure XP beads
were used to clean up the libraries. A first Polymerase Chain
Reaction (PCR) amplification step (15 cycles of 98◦C for 10 s,
60◦C for 30 s, and 72◦C for 30 s) was performed to selectively
enrich those DNA fragments that have adapter molecules on both
ends and also to amplify the amount of DNA in the library.
After validation of the libraries, the first hybridization step was
performed using exome capture probes. Before hybridization
a 2-plex pool of libraries was made, by combining 200 ng of
each DNA library. The hybridization was performed by 18 cycles
of 1 min incubation, starting at 94◦C, and then decreasing
2◦C for cycle. Then streptavidin-coated magnetic beads were
used to capture probes hybridized to the target regions. The
enriched libraries were then eluted from the beads and prepared
for a second round of hybridization. This second hybridization
(18 cycles of 1 min incubation, starting at 94◦C, and then
decreasing 2◦C per cycle) was required to ensure high specificity
of the capture regions. A second capture with streptavidin-
coated beads was performed, followed by two heated wash
procedures to remove the non-specific binding from the beads.
The enriched libraries were then eluted from the beads and
cleaned up by the AMPure XP beads, prior to a second PCR
amplification. The amplification step was performed by 10 cycles
(98◦C for 10 s, 60◦C for 30 s, and 72◦C for 30 s) followed by
a second PCR clean up. Finally, the libraries were quantitated
by quantitative PCR using the KAPA Library Quantification Kit-
Illumina/ABI Prism R© (Kapa Biosystems, Inc., Wilmington, MA,
USA) and validated using the Agilent High Sensitivity DNA Kit
on a Bioanalyzer. The size range of the DNA fragments was
measured to be in the range of 200–650 bp and peaked around
250 bp.
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Libraries were normalized to 12 pM and subjected to cluster
and the single read sequencing was performed for 150 cycles
on a MiSeq instrument (Illumina, Inc. San Diego, CA, USA),
according to the manufacturer’s instructions. Finally, the libraries
generated were loaded for clustering on aMiSeq Flow Cell v3 and
sequenced through the MiSeq Instrument.
Gene Expression Data Processing
CASAVA (version 1.8.2, Illumina) software was used to
demultiplex reads into specific sample and groups of the indexes.
Each sample was mapped against its reference sequences “Homo
sapiens UCSC hg19” using RNA-Seq Alignment version 1.0.0
with its default parameters, in particular for the Read mapping
was used the TopHat 2 (Bowtie 1). The Fragments Per Kilobase
Of Exon Per Million Fragments Mapped (FPKM) values were
calculated for each sample using the normalized reads counts
for each annotated gene [(1000 × read count) ÷ (number of
gene covered bases× number of mapped fragments in million)].
Unmapped reads were removed, retaining only read pairs with
both reads aligned to the reference sequences “Homo sapiens
UCSC hg19.” The comparison between two different samples was
visualized by a scatter plot of the LOG2 of the FPKM.
Bioinformatics Analysis of Genes
Differentially Expressed
Once identified the genes differentially expressed between CTR-
hGMSCs and CBD-hGMSCs, the enrichment analyses of the
Gene Ontology processes (GO) and the pathway analyses were
conducted using the online free databases such as bioDBnet
(Mudunuri et al., 2009), STRING (Szklarczyk et al., 2015) and
KEEG (Kanehisa et al., 2016). This strategy, based on testing
multiple tools, is recommended in order to obtain the most
satisfactory results (Rhee et al., 2008). We considered only the
GO categories or KEGG pathways reported to be significantly
enriched.
Immunocytochemistry
Cells on coverslips (10 mm, Thermo SCIENTIFIC, Germany)
were fixed with 4% paraformaldehyde at room temperature
for 20 min, followed by phosphate buffered saline (PBS, pH
7.5) washes. Then, cells were incubated with 3% hydrogen
peroxide (H2O2) at room temperature for 15 min to suppress
the endogenous peroxidase activity. Following three washes
with PBS, cells were blocked with horse serum + 0.1% Triton
X-100 for 20 min followed by incubation for overnight at 4◦C
with primary antibodies against examined proteins: Caspase-1
(CASP1, 1:100, Abcam), Interleukin-18 (IL-18, 1:100, Abcam),
NLR family pyrin domain containing 3 (NRLP3/NALP3, 1:100,
R&D Systems), Bcl2 associated X (Bax, 1:100 Santa Cruz
Biotechnology Inc) and Bcl-2 (1:100 Santa Cruz Biotechnology
Inc). After PBS wash, cells were incubated with biotinylated
secondary antibody (1:200, Vector Laboratories, Burlingame,
CA) and streptavidin ABComplex-HRP (ABC-kit from Dako,
Glostrup, Denmark). The immunostaining was developed with
peroxidase substrate kit DAB (Vector Laboratories, Burlingame,
CA) (brown color; positive staining) and counterstaining with
nuclear fast red (Vector Laboratories, Burlingame, CA) (pink
background; negative staining).Microscopy was performed using
light microscopy (LEICADM2000 combined with LEICA ICC50
HD camera). Immunocytochemistry images were assessed for
densitometry analysis using LEICA Application Suite V4.2.0
software to calculate the percentage of positive staining of
the cells. All images are representative of three independent
experiments.
Protein Extraction and Western Blot
Analysis
In order to extract proteins, cells were washed with ice-cold PBS
and lysed using Buffer A [320 mM Sucrose, 10 mM, 1 mMEGTA,
2 mM EDTA, 5 mM NaN3, 50 mM NaF, β-mercaptoethanol,
and protease/phosphatase inhibitor cocktail (Roche, USA)] in
ice for 15 min, followed by centrifugation at 1000 g for 10 min
at 4◦C. The supernatant was served as cytosolic extract. The
pellet was further lysed using Buffer B [150 mM NaCl, 10 mM
Tris-HCl (pH 7.4), 1 mM EGTA, 1 mM EDTA, Triton X-100,
and protease/phosphatase inhibitor cocktail (Roche, USA)] in
ice for 15 min, followed by centrifugation at 15,000 g for 30
min at 4◦C. The supernatant was collected and used as nuclear
extract. Then, the concentrations of proteins were assessed
by using the Bio-Rad Protein Assay (Bio-Rad, Segrate, Italy)
using BSA as standard, and 30 µg of total extracts from each
sample were analyzed. Total proteins were separated on sodium
dodecyl sulfate-polyacrylamide mini-gels and then transferred
onto polyvinylidene fluoride membranes (Immobilon-P Transfer
membrane, Millipore), blocked with PBS containing 5% nonfat
dried milk (PM) for 45 min at room temperature, and
subsequently incubated at 4◦C overnight with a specific antibody
for the cannabinoid receptor 1 (CB1R, 1:200; ThermoFisher,
Scientific), for caspase-1 (CASP1, 1:1000, Abcam) and for pro-
caspase-1 (pro-CASP1, 1:1000, Abcam).
The membranes were incubated with secondary antibodies,
HRP-conjugated goat anti-mouse IgG or HRP-conjugated goat
anti-rabbit IgG (1:2000; Santa Cruz Biotechnology, Inc.) for 1
h at room temperature. To ascertain that blots were loaded
with equal amounts of protein lysates, they were also incubated
with antibody for GAPDH HRP Conjugated (1:1000; Cell
Signaling Technology). The relative expression of protein bands
was visualized using an enhanced chemiluminescence system
(Luminata Western HRP Substrates, Millipore) and protein
bands were acquired and quantified with ChemiDocTM MP
System (Bio-Rad) and analyzed by using the software Image J.
Statistical Data Analysis
The statistical analyses to determine the proportion of
differentially expressed genes between two samples on the
read counts were performed with the Cuﬄinks Assembly & DE
package version 2.0.
Immunocytochemical and Western blot data were analyzed
by using the software GraphPad Prism 6.0 (GraphPad Software,
La Jolla, CA) and applying the one-way ANOVA statistic test,
followed by a Bonferroni post-hoc test for multiple comparisons.
A p-value of < 0.05 was considered statistically significant.
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RESULTS
Cytofluorimetric Characterization of
hGMSCs
Flow cytometry was used to assess the MSC immunoprofile.
In Figure 1, section A, we have shown that hGMSCs
expressed surface molecules such as CD13, CD29,
CD44, CD73, CD90, CD105, CD 146, CD166, and the
human leukocyte antigen (HLA)-ABC, while they were
negative for the subsequent markers: CD14, CD31, CD34,
CD45, CD117, CD133, CD326, HLA-DR, according
to the minimal criteria for defining MSCs (Dominici
et al., 2006). Moreover, hGMSCs expressed pluripotency
associated markers like OCT3/4, NANOG, SOX2,
SSEA4.
Morphological and Functional
Characterization of hGMSCs
The first CFU appeared after 6 days of the initiation of the
primary culture. Under optical microscopy, primary cells
showed spindle-shaped with fibroblastic-like morphology
(Figure 1B). No differences in morphological features
have been evidenced after CBD treatment for 24 h
(Figure 1C). Moreover, we have proved the multipotent
potential of hGMSCs to differentiate in osteoblasts and
adipocytes. During osteogenic differentiation, at day 21, after
Alizarin Red S staining, mineralized extracellular deposits
were observed in CTR-hGMSCs and in CBD-hGMSCs
(Figures 1D,E). For adipogenic differentiation, Oil Red
O solution stained oil globules containing many lipid-
rich vacuoles at cytoplasmic level in CTR-hGMSCs and in
CBD-hGMSCs 28 days of culture in adipogenic medium
(Figures 1E,F).
Global Gene Expression
To explore the effect of CBD treatment on the
expression profile of the hGMSCs, we performed a
high-throughput sequencing through the NGS platform.
This technique allowed us to map about 14.320
FIGURE 1 | Characterization of gingiva-derived mesenchymal stem cells (hGMSCs). (A) Flow cytometry phenotype of hGMSCs at the second passage during
in vitro cultures of surface (CD13, CD14, CD29, CD31, CD34, CD44, CD45, CD73, CD90, CD105, CD117, CD133, CD146, CD166, CD326, HLA-ABC, and HLA-DR)
and intracellular (SSEA4, Oct3/4, Sox2, and NANOG) marker expression levels were detected. Red histograms show the distribution of each antigen expression,
whereas Blue histograms represent the distribution of the respective background control. (B) The gingival connective tissue-derived mesenchymal stem cells showed
colony-forming potency and plastic-adherent characteristics at day 6. (C) CBD-hGMSCs and CTR-hGMSCs showed spindle-shaped, fibroblast-like morphology
under light microscope. (D) Osteogenic differentiation at day 21 after Alizarin Red S staining highlighted calcium deposits in CTR-hGMSCs and in (E) CBD-hGMSCs.
(F) CTR-hGMSCs and (G) CBD-hGMSCs induced to a dipogenic differentiation after 28 days showed many oil droplets at cytoplasmic level stained with Oil Red O
solution. Mag: 10X; bar: 200µm.
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TABLE 1A | CBD treatment suppressed genes linked to apoptosis, inflammatory and innate immune responses.
Gene Description Go processes CTR-hGMSCs
Exp_Value
CBD-hGMSCs
Exp_Value
LOG10FC FDR Q_VALUE
AQP1 Aquaporin 1 Apoptotic process, regulation of apoptotic process
extrinsic apoptotic signaling pathway
6.01 0.00 −5.78 9.79e-05
CAPN3 Calpain 3 Apoptotic process, regulation of apoptotic process,
inflammatory response
5.16 0.00 −5.71 9.79e-05
CARD16 Caspase recruitment
domain family member 16
Regulation of apoptotic process, inflammatory
response
6.60 0.00 −5.82 9.79e-05
CASP1 Caspase 1 Apoptotic process, regulation of apoptotic process,
inflammatory response
8.22 0.00 −5.92 9.79e-05
CASP6 Caspase 6 Apoptotic process, regulation of apoptotic process, 2.19 0.00 −5.3 9.79e-05
GAS1 Growth arrest specific 1 Regulation of apoptotic process, regulation of
response to stimulus
14.63 0.00 −6.17 2.96e-02
H1FX H1 histone family member X Apoptotic DNA fragmentation, nucleosome
assembly
6.41 0.00 −5.81 9.79e-05
IFI6 Interferon alpha inducible
protein 6
Apoptotic process, innate immune response 5.07 0.00 −5.71 9.79e-05
ING4 Inhibitor of growth family
member 4
Apoptotic process, regulation of apoptotic process 5.88 0.00 −5.77 9.79e-05
MIEN1 Migration and invasion
enhancer 1
Apoptotic process, regulation of apoptotic process,
cell redox homeostasis
16.44 0.00 −6.22 9.79e-05
PDCL3 Phosducin like 3 Apoptotic process, protein folding 11.78 0.00 −6.07 9.79e-05
PPP3CC Protein phosphatase 3
catalytic subunit gamma
Apoptotic process, positive regulation of apoptotic
process
8.82 0.00 −5.95 9.79e-05
PTN Pleiotrophin Positive regulation of apoptotic process 6.62 0.00 −5.82 9.79e-05
PYCARD PYD and CARD domain
containing
Regulation of apoptotic process, inflammatory
response, innate immune response
8.12 0.00 −5.91 9.79e-05
SIVA1 SIVA1 apoptosis inducing
factor
Apoptotic process, regulation of apoptotic process 21.16 0.00 −6.33 9.79e-05
WWOX WW domain containing
oxidoreductase
Apoptotic process, regulation of apoptotic process 8.16 0.00 −5.91 2.14e-02
FLT3LG fms related tyrosine kinase 3
ligand
Regulation of apoptotic process, inflammatory
response
11.22 0.00 −6.05 9.79e-05
DDT D-dopachrome tautomerase Inflammatory response 16.71 0.00 −6.22 9.79e-05
NLRP3 NLR family, pyrin domain
containing 3
Inflammatory response, apoptotic process 3.17 0.00 −5.34 9.79e-05
BRCC36 BRCA1/BRCA2-containing
complex subunit 3
Inflammatory response, G2 DNA damage
checkpoint
5.02 0.00 −5.70 9.79e-05
LY96 Lymphocyte antigen 96 Inflammatory response, innate immune response,
regulation of apoptotic process
14.95 0.00 −6.17 9.79e-05
ATAT1 Alpha tubulin
acetyltransferase 1
Inflammatory response 4.88 0.00 −5.69 9.79e-05
PLGRKT Plasminogen receptor with
a C-terminal lysine
Inflammatory response 5.68 0.00 −5.75 9.79e-05
HLA-H Major histocompatibility
complex, class I, H
Antigen processing and presentation, regulation of
immune response
8.08 0.00 −5.91 9.79e-05
GNG10 G protein subunit
gamma 10
G-protein coupled receptor signaling pathway,
signal transduction
6.37 0.00 −5.80 9.79e-05
The differential expression between CBD-hGMSCs and CTR-hGMSCs is given in Fold Change (log10 FC). GO processes indicate their classification in different biological processes.
Instead, the statistical significance is indicated by False Discovery Rate (FDR), p-values ≤ 0.05 were considered statistically significant.
TABLE 1B | CBD suppressed the expression of genes belonging to the
NOD-like receptor signaling pathway.
KEGG pathway Gene symbol FDR
NOD-like receptor signaling pathway NLRP3, CASP1, PYCARD 0.006
for the CTR-hGMSCs group and 10.158 for CBD-
hGMSCs group. Statistical analysis revealed 5843 genes
differentially expressed following CBD treatment, among
which 2798 were down-regulated, while 3045 were
up-regulated.
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TABLE 2A | CBD treatment reduced the expression of pro-inflammatory genes.
Gene Description Go processes CTR-hGMSCs CBD-hGMSCs LOG10 FC FDR
Exp_Value Exp_Value Q_VALUE
CARD8 Caspase Recruitment Domain
Family Member 8
Regulation of inflammatory response 2.87 0.91 −0.49 3.52e-04
CTSB Cathepsin B Response to cytokine, regulation of inflammatory
response, regulation of defense response
150.13 104.14 −0.15 9.79e-05
HSP90AA1 Heat shock protein 90 alpha
family class A member 1
Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
423.83 724.1 0.23 9.79E-05
IFNGR1 Interferon Gamma Receptor 1 Response to cytokine, regulation of immune response,
regulation of defense response
14.43 7.32 −0.29 9.79e-05
IFNGR2 Interferon Gamma Receptor 2 Response to cytokine, regulation of immune response,
regulation of defense response
40.42 35.86 −0.05 4.5e-02
IL11RA Interleukin 11 Receptor Subunit
Alpha
Response to cytokine 23.77 12.22 −0.28 9.79e-05
IL13RA1 Interleukin 13 Receptor Subunit
Alpha 1
Response to cytokine, inflammatory response, cell
surface receptor signaling pathway,
6.01 0.60 −0.99 9.79e-05
IL1B Interleukin 1 Beta Response to cytokine, inflammatory response,
regulation of inflammatory response
6.48 4.71 −0.13 1.91 e-03
IL1R1 IL1R1 Interleukin 1 Receptor
Type 1
Response to cytokine, regulation of defense response,
regulation of inflammatory response
6.48 4.71 −0.13 1.90e-03
IL6ST Interleukin 6 Response to cytokine, regulation of immune response,
regulation of defense response, regulation of
inflammatory response
24.86 22.91 −0.03 0.021783
IL18 Interleukin 18 Response to cytokine, inflammatory response,
regulation of inflammatory response
0.89 -1.06 −0.31 2.58e-05
MAPK1 Mitogen-Activated Protein
Kinase 1
Response to cytokine, inflammatory response, regulation
of inflammatory response, MAPK cascade
35.18 27.59 −0.10 2.82e-03
MAPK12 Mitogen-Activated Protein
Kinase 12
Inflammatory response, regulation of inflammatory
response, MAPK cascade
7.16 4.35 −0.21 8.23e-03
MAPK14 Mitogen-Activated Protein
Kinase 14
Inflammatory response, regulation of immune response,
regulation of defense response
14.06 5.83 −0.38 9.79e-05
MMP3 Matrix Metallopeptidase 3 Inflammatory response, regulation of inflammatory
response, extracellular matrix disassembly
85.78 55.05 −0.19 9.79e-05
MYD88 Myeloid Differentiation Primary
Response Gene 88
Response to cytokine, regulation of immune response,
regulation of defense response, regulation of
inflammatory response
12.55 2.62 −0.67 9.79e-05
NFKB2 Nuclear Factor Kappa B
Subunit 2
Response to cytokine, regulation of immune response 8.64 5.53 −0.19 4.50e-05
NFKBIA NFKB Inhibitor Alpha Response to cytokine, inflammatory response, negative
regulation of NF-kB transcription factor activity
28.48 34.80 0.08 1.34e-02
RELA RELA Proto-Oncogene, NF-κB
Subunit
Response to cytokine, regulation of immune response,
regulation of defense response
17.21 11.29 −0.18 9.79e-05
STAT3 Signal Transducer And Activator
Of Transcription 3
Response to cytokine, inflammatory response, regulation
of inflammatory response
45.10 20.27 −0.34 9.79e-05
STAT6 Signal Transducer And Activator
Of Transcription 6
Response to cytokine, regulation of immune response,
inflammatory response, regulation of inflammatory
response
47.66 37.66 −0.10 9.79e-05
Gene expression levels of CTR-hGMSCs and CBD-hGMSCs are given in log10, as well as the Fold Changes (FC). GO processes indicate their classification in different biological
processes. Instead, the statistical significance is indicated by the False Discovery Rate (FDR), p-values ≤ 0.05 were considered statistically significant.
CBD Treatment Modulated the Expression
of Genes Related to Inflammation, Immune
Response and Apoptosis
Interestingly, here we found that CBD totally inhibited the
expression of 25 genes in CBD-hGMSCs (False Discovery Rate
(FDR), q-value < 0.05). According to GO processes, these
suppressed genes belonging to the following GO categories:
apoptotic process and regulation of apoptotic process (H1FX,
CASP6, PDCL3, SIVA1, ING4, AQP1, MIEN1, CAPN3,CASP1,
WWOX, IFI6, GAS1, PTN, PPP3CC, CARD16, PYCARD),
inflammatory response (FLT3LG, DDT, NLRP3, BRCC36, LY96,
ATAT1, PLGRKT) and innate immune response (HLA-H) and
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TABLE 2B | CBD negatively modulated the transcription of genes involved in NOD-like receptor signaling pathway and other inflammatory pathways.
KEGG pathway Gene symbol FDR
NOD-like receptor signaling pathway CARD8, IL1B, IL18, MAPK1, MAPK12, MAPK14, NFKBIA, RELA 2.3e-14
TNF signaling pathway MMP3, IL1B, MAPK1, MAPK12, MAPK14, NFKBIA, RELA 1.43e-09
Jak-STAT signaling pathway STAT6, IFNGR1, IFNGR2, IL13RA1, IL6ST, STAT3 1.43e-08
NF-kB signaling pathway MYD88, IL1B, IL1R1, NFKBIA, NFKB2, RELA 2.19e-08
The statistical significance is indicated by FDR, p-values of ≤ 0.05 were considered statistically significant.
FIGURE 2 | Immunocytochemical staining for IL18, NALP3 and CASP1. CBD-hGMSCs showed a negative staining for IL-18, NALP3, and CASP1 compared to
CTR-hGMSCs. Instead, hGMSCs-SR141716A and hGMSCs-AM630 showed a significant positive staining for IL-18, NALP3, and CASP1 compared to
CBD-hGMSCs. The graph represented the densytometric quantitative analysis. For IL-18 CTR-hGMSCs vs. CBD-hGMSCs ***p < 0.001; SR141716A-hGMSCs vs.
AM630-hGMSCs ****p < 0.0001. For NALP3 CTR-hGMSCs vs. CBD-hGMSCs **p < 0.01; SR141716A-hGMSCs vs. AM630-hGMSCs **p < 0.01. For CASP-1
CTR-hGMSCs vs. CBD-hGMSCs ***p < 0.001; SR141716A-hGMSCs vs. AM630-hGMSCs ***p < 0.001.
signal transduction (GNG10). In Table 1A have been reported
the GO process categories, the expression levels of CTR-hGMSCs
and CBD-hGMSCs (Exp_Value), the Fold Change (FC) and the
False Discovery Rate (FDR) for each aforementioned genes.
However, by interrogating the KEGG database for pathway
analysis, we found only a pathway predicted to be statistically
significant for this class of genes: the NOD-like receptor signaling
(FDR = 0.006; Table 1B), an intracellular platform for the
assembly of protein complexes known as inflammasomes, which
includes NLRP3, CASP1, and PYCARD (Table 1A) (Shaw et al.,
2011). NALP3 is a NOD-like receptor and together with the
adaptor protein PYCARD forms a CASP1 activating complex,
in response to a dangerous stimulus, known as the NALP3
inflammasome, which is the best characterized inflammasome
complex (Schroder and Tschopp, 2010). Active CASP1 can
eventually process IL-1 and IL-18 precursors, enhancing multiple
pro-inflammatory pathways, including NF-κB, the mitogen-
activated protein kinase (MAPK) and Interferon (IFN) (Fuentes-
Antrás et al., 2014). Our gene expression results indicated
a downregulation of the genes implicated in the NALP3-
inflammasone pathway in CBD-HGMSCs.
Although for the other genes suppressed by CBD and reported
in Table 1A, none statistical pathways were predicted by the
KEEG software, these preliminary results have encouraged us
to further investigate the potential of CBD to modulate genes
implicated in immune response, inflammation and apoptosis.
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FIGURE 3 | Western blot analysis for CASP1. CASP1 expression is
decreased in CBD-hGMSCs compared to CTR-DMSO). The levels of CASP1
are significant increase in SR141716A-hGMSCs compared with
CBD-hGMSCs. CTR-hGMSCs vs. CBD-hGMSCs *p < 0.05;
SR141716A-hGMSCs vs. AM630-hGMSCs ***p < 0.001.
CBD Treatment Attenuated the Expression
of Pro-Inflammatory Genes
Gene expression profiling has showed that CBD treatment
in hGMSCs downregulated the expression of genes codifying
for pro-inflammatory cytokines (IL6ST, IL-1β, and IL-18),
Interleukin receptors or subunits (IL1R1, IL11RA, IL13RA),
the Toll-like receptor adaptor (MYD88), Interferon Gamma
Receptors (IFNGR1 and IFNGR2), Mitogen-Activated Protein
Kinases (MAPK1, MAPK12, and MAPK14), transcription
factors (STAT3 and STAT6), the complex of NFκB (NFKB2,
NFKB3/RELA), and the Matrix Metallopeptidase 3 (MMP3)
(Table 2A). Specifically, these genes can be classified in
the following GO terms: response to cytokine, regulation
of immune response, regulation of defense response. etc.
(Table 2A). The GO annotations, the expression levels (Exp-
Value), the fold changes (FC) and the False Discovery
Rates (FDR) of these genes differentially expressed between
CBD-hGMSCs and CTR-hGMSCs have been reported in
Table 2A.
According to KEEG pathway predictions, this group of genes
can be clustered in the most following significant pathways:
the NOD-like receptor signaling pathway, the TNF signaling
pathway, the Jak-STAT signaling pathway and the NF-kB
signaling pathway (Table 2B). These results altogether indicated
that CBD negatively regulates differential pathways involved in
inflammatory responses, but in particular the NOD-like receptor
signaling pathway.
CBD Prevented the Activation of the
NALP3-Inflammasome in hGMSCs
The NALP3-inflammasome has been correlated with several
inflammatory conditions and increasing evidences have
indicated that the inhibition of the inflammasome could be
a promising strategy for treating inflammatory disorders and
also for preventing allograft-rejections in cell-based therapies
(Foley, 2013; Coll et al., 2015; Shah et al., 2015). Our gene
expression data have revealed a downregulation of several
genes codifying for key players of the NALP3-inflammasome
in CBD-hGMSCs. In order to confirm the ability of CBD
to modulate the NALP3-inflammasome, we have performed
immunocytochemistry and western blot analyses. Achieved
immune-localization data have shown that NALP3, IL-18,
and CASP1 were completely negative in CBD-hGMSCs, in
a significant manner compared to CTR-hGMSCs (Figure 2).
A representative negative control of immunocytochemistry
is showed in Supplementary Material. The expression levels
of CASP1 were also investigated by Western blotting and
normalized on pro-CASP1, showing a reduced CASP1
expression in CBD-hGMSCs compared to CTR-hGMSCs
(Figure 3).
Moreover, in order to understand whether the inhibition
of the inflammasome by CBD could be mediated by the
cannabinoid receptors (CB1R and CB2R), we have pre-
treated hGMSCs with selective receptor antagonists for CB1R
(SR141716A) and CB2R (AM630), before CBD treatment for
24 h. Immunochemistry has showed that SR141716A reverted
completely the downregulation of NALP3, IL-18, and CASP1
induced by CBD, instead AM630 was also able to antagonize only
partially the CBD effects. Western blotting has confirmed that
blocking CB1R reverted the CBD-mediated reduction of CASP1
(Figure 3).
Moreover, we evaluated the expression of NF-κB since it
is considered as a regulator of NALP3 activity (Bauernfeind
et al., 2009), finding that NF-κB levels were statically reduced
by CBD treatment, as demonstrated by immunocytochemistry
analyses (Figure 4). These results suggested that CBD promotes
the inactive state of the NALP3-inflammasome pathway.
Moreover, only the CB1 agonist has shown to antagonize
the CBD-mediated reduction of NF-kB, indicating that CBD
may act in a CB1R dependent manner, while CB2R is likely
to be not involved in this signaling. These results might
suggest that CBD can interact with both CB1R and CB2R,
although it acts preferably via a CB1R mechanism, showing
a selectivity for the CB1R respect to the CB2R in hGMSCs.
Additionally, Western blot results (Figure 5) have showed
an increased CB1R expression in CBD-hGMSCs compared
to control groups (DMSO-hGMSCs and CTR-hGMSCs). A
schematic representation of the NALP3-inflammasome pathway
in CBD-hGMSCs is illustrated in the Figure 6.
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FIGURE 4 | Immunocytochemical staining for Bax, Bcl2 and NFκB. CBD-hGMSCs showed a negative staining for Bax, a reduced expression for NF-KB and a
positive staining for Bcl2, compared to CTR-hGMSCs. hGMSCs-SR141716A showed a marked positive cytoplasmatic/nuclear staining for NF-kB, as indicated by the
arrows. Moreover, hGMSCs-SR141716A showed an increased nuclear expression for Bax and reduced expression for Bcl2 at both cytoplasmatic and nuclear
compartment, compared to CBD-hGMSCs. Instead, hGMSCs-AM630 showed a reduced expression for Bax and Bcl2 compared to CBD-hGMSCs. Whereas, no
differences statistically differences were found for the NF-kB expression between CBD-hGMSCs and hGMSCs-AM630. The graph represented the densytometric
quantitative analysis. For Bax CTR-hGMSCs vs. CBD-hGMSCs ***p < 0.001; SR141716A-hGMSCs vs. AM630-hGMSCs ****p < 0.0001. For Bcl2 CTR-hGMSCs vs.
CBD-hGMSCs *p < 0.05; SR141716A-hGMSCs vs. AM630-hGMSCs ***p < 0.001. For NF-kB CTR-hGMSCs vs. CBD-hGMSCs *p < 0.05; SR141716A-hGMSCs
vs. AM630-hGMSCs ****p < 0.0001.
CBD Reduced the Expression of
Pro-Apoptotic Genes
Following infusion of MSCs, the hostile environment could
induce apoptosis few hours after transplantation. Thus,
researchers had tried to develop new strategies to improve
survival of MSCs, such as preconditioning of MSCs by
cultivation under peroxide hydrogen, hypoxic and serum
deprivation (Farzaneh Taban et al., 2016).
Here, we have previously showed that CBD treatment in
hGMSCs inhibited the expression of several genes correlated
to the apoptosis, according to the GO biological processes.
In this study, we have also found that CBD downregulated
the expression of additional genes related to apoptosis, among
which we detected genes codifying for the TNF receptor
superfamily members (TNFRSF10B, TNFRSF11B, TNFRSF12A,
and TNFRSF19), the initiator caspases (CASP4 and CASP8), the
pro-apoptotic mediators (BAX, BAD, BID, BCL7B, BCL2L13,
CYCS), and the apoptotic peptidase APAF-1 (Table 3A). Some
of these genes were predicted by KEGG to be involved in
the apoptotic pathway in a significant manner, as reported in
Table 3B.
In parallel, CBD enhanced the transcription of the
phosphoinositid-3 kinase (PIK3) subunits (PIK3CA and
PIK3CB) and AKT1 serine/threonine kinase 1 (AKT1). The
upregulation of the PI3K/Akt signaling has been associated with
increased stem cell survival (Hossini et al., 2016).
Moreover, we have observed a negative staining for the pro-
apoptotic mediator Bax in CBD-hGMSCs and positive staining
for the anti-apoptotic protein Bcl-2, by immunocytochemistry.
These data confirmed that CBD treatment inhibited apoptosis in
hGMSCs (Figure 4). By pre-treating cells with the cannabinoid
receptor agonists, we found that this inhibition seems to be
mainly mediated by the CB1R (Figure 4). Our results suggested
that CBD treatment may improve stem cell survival through
two complementary strategies: by reducing the expression of
pro-apoptotic mediators and by promoting the anti-apoptotic
ones.
CBD Modified the Immunophenotype of
hGMSCs
MSCs have been reported to exert immunosuppressive properties
in the host (Schu et al., 2012). However, evidence also suggests
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FIGURE 5 | Western blot analysis for CB1R. CB1R expression is increased
in CBD-hGMSCs compared to control groups (DMSO-hGMSCs and
CTR-hGMSCs). ***p < 0.001. ns, no statistical differences.
that they can also elicit a allogeneic immune response (Nauta
et al., 2006). Thus, we investigated whether CBD was able
to modulate the cell surface expression of immunogenic
markers. We detected a differential expression of the well-
known mesenchymal markers: specifically CD13, CD29,
and CD73 were upregulated in CBD-hGMSCs (Table 4),
while CD44, CD90, and CD166 were downregulated
(Table 4).
Furthermore, we found that following CBD treatment, other
genes codifying for surface antigens were differentially expressed,
in particular those involved in the inhibition of the immune
system activation such as CD47, CD55, and CD276 were
upregulated whereas, the expression levels of the costimulatory
molecules CD40, CD46, CD81, and CD82, as well as the levels
of the T-cells and macrophage activators CD59, CD68, and
CD99 and, the immune surface markers CD109 and CD151
were decreased by CBD (Table 5). The GO process categories,
the expression levels (Exp_Value), the fold change (FC) and the
False Discovery Rate (FDR) have been given in Table 5. None
pathway statistically significant was found for this group of genes,
according to KEEG database.
DISCUSSION
The ability of hGMSCs to self-renew, to differentiate into
different tissues, together with their easy accessibility and
abundance, renders them a promising alternative source of
MSCs for regenerative medicine. However, prior to their clinical
applications, further investigations are required to ensure that
they do not elicit immune or inflammatory responses that could
affect their efficacy and survival in vivo.
In this work, we asked whether preconditioning donor cells
(hGMSCs) with CBD, before transplantation in the host, could
modify their gene expression profile, improving their therapeutic
efficacy.
Global gene expression data have showed that CBD
modulated the expression of 5843 genes in hGMSCs, among
which, we found that CBD treatment downregulated the
expression of genes correlated to inflammation and apoptosis.
Specifically, we have detected a reduced expression of several
key genes involved in the NOD-like receptor signaling and
more specifically, belonging to the NALP3 inflammasome
complex. The NALP3-inflammasome could be considered as an
integrated signaling system which converges multiple signaling
pathways such as cell death and innate immune responses
(Nakanishi et al., 2001). Indeed, following a dangerous stimulus,
NALP3 binds its adaptor protein PYCARD to assembly the
inflammasome complex which recruits CASP1 (Latz et al., 2013).
CASP1 in turn promotes the cleavage of the pro-inflammatory
cytokines such as IL-1β and IL-18 (Lalor et al., 2011), which
promote the inflammatory and immune responses (Nakanishi
et al., 2001; Netea et al., 2010). Here, we have found that
CBD promotes the inactive state of the NALP3-inflammasome
pathway in hGMSCs by inhibiting some key members of this
signaling, including NALP3, CASP1, and IL18, via a preferably
CB1R mechanism, which does not exclude completely the
CB2R involvement. Moreover, we have found that CBD led to
increased CB1R expression in hGMSCs. These findings are in
according with previous studies which have showed an increased
CB1R expression following in vitro exposure to exogenous or
endogenous cannabinoids (Börner et al., 2007; Laprairie et al.,
2013).
Additionally, we have observed a reduced expression of
NF-κB, a crucial transcription factor which promotes the
transcription of several pro-inflammatory mediators, including
NALP3, both at transcriptional and protein levels. Moreover,
the blockade of CB1R, through the administration of a
specific antagonist, led to increased NF-kB expression, while no
statistically changes were observed after the exposure to CB2R
antagonist, indicating a direct involvement of CB1R in this
signaling.
Overall, our results have suggested that CBD negatively
regulated the NALP3-inflammasome activation, mainly via
a CB1R mechanism. Although a direct modulation of the
inflammasome complex by the cannabinoid receptors CB1R
and CB2R, has been already investigated by previous studies,
it role remains still controversial. Indeed, it has been reported
that CB2R activation, by inhibiting the NLRP3-inflammasome
pathway, played a protective role in experimental models of
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FIGURE 6 | Proposed molecular mechanism for CBD modulation of the genes of the NALP3-inflammasome in hGMSCs. The activation of the
NALP3-inflammasome is regulated by NF-kB which promotes NALP3 deubiquitination via activation of BRCC36. NALP3 interacts with CASP1 through CARD5 and
CARD8. Activated CASP1 cleaves pro-IL-1 beta and pro-IL-18, leading to subsequent release of mature cytokines which trigger inflammation. In parallel, IL-18
indirectly via CASP8 and CASP6 can stimulate apoptosis. In hGMSCs, BRCC6, NALP3 and CASP1 transcripts are suppressed (violet) and the expression of the
downstream mediators (CARD5, CARD8, IL1β, IL18, CASP8) is downregulated (green), while CASP8 is totally suppressed (violet). Instead, the pro-survival AKT1 and
MDM2 were upregulated (red), leading to the downregulation of BAX and BAD (green).
inflammatory and autoimmune disorders (Shao et al., 2014; Ke
et al., 2016). Conversely, Jourdan et al. (2013) have showed
that CB1R mediated the NALP3-inflammasome activation and,
thus inflammation in macrophages derived from rat model of
diabetes.
However, accumulating evidences have highlighted the
NALP3 inflammasome as potential target for treating
inflammation and for preventing graft failures (Foley, 2013;
Jankovic et al., 2013; Coll et al., 2015), thus we proposed that
CBD treatment, by antagonizing the NALP3 inflammasome
activation in hGMSCs, renders them less predispose to
trigger inflammation, thus more resistant to the hostile
microenvironment, once transplanted in the host. All these
evidences suggested that preconditioning hGMSCs with CBD
might be a strategy to improve cell engraftment in the context of
stem cell-based therapy.
Following MSCs infusion, the hostile environment could
induce apoptosis few hours after transplantation, as consequence,
new strategies to counteract apoptosis or to improve survival
of MSCs are needed. In this study, we have showed that CBD
pre-treatment in hGMSCs correlated with the downregulation
of several genes involved in apoptosis. Moreover, we have
demonstrated that Bax expressionwas totally suppressed in CBD-
hGMSCs, while Bcl2 levels were increased, confirming an anti-
anti-apoptotic role for CBD in these cells. We have also found
that this pro-survival effect of CBD could be mediated by the
CB1R. These results are corroborated by other studies which have
showing that CB1R activation correlated with reduced apoptosis
(Gómez del Pulgar et al., 2000) and increased mesenchymal stem
cell survival (Gowran et al., 2013).
Immune rejection is one of the major complication that
may occur with stem cell transplantation. The main targets
for the immune response to transplanted grafts are major
histocompatibility complex (MHC)-encoded molecules
(Ayala García et al., 2012). Despite, the hGMSCs have
showed to express the human leukocyte antigen (HLA)
major histocompatibility complex (MHC) class I and to be
negative for MHC II (Castro-Manrreza et al., 2015), they
have still not been adequately characterized with respect
to their immunogenic properties. Several studies reported
that CBD could have a role in the inhibition of the graft
rejection T-cells mediated (Kaplan et al., 2008; Nagarkatti et al.,
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TABLE 3A | CBD treatment reduced the expression of pro-apoptotic genes.
Gene Description Go processes CTR-hGMSCs CBD-hGMSCs LOG10FC FDR
Exp_Value Exp_Value Q_VALUE
AKT1 AKT serine/threonine
kinase 1
Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
47.16 59.52 0.10 9.79e-05
APAF1 Apoptotic peptidase
activating factor 1
Regulation of apoptotic process, positive regulation of
cysteine-type endopeptidase activity involved in
apoptotic process, regulation of apoptotic signaling
pathway
7.14 5.34 −0.12 2.77e-03
BAD BCL2 associated agonist
of cell death
Positive regulation of cysteine-type endopeptidase
activity involved in apoptotic process, regulation of
apoptotic signaling pathway
12.89 11.18 −0.06 4.34e-05
BAX BCL2 associated X,
apoptosis regulator
Regulation of apoptotic process, extrinsic apoptotic
signaling pathway
37.48 13.20 −0.45 9.79e-05
BCL2L13 BCL2 like 13 Regulation of apoptotic process, positive regulation of
cysteine-type endopeptidase activity involved in
apoptotic process
9.96 4.33 −0.36 9.79e-05
BCL7B BCL tumor suppressor
7B
Regulation of apoptotic process, regulation of apoptotic
signaling pathway
8.40 1.58 −0.72 9.79e-05
BID BH3 interacting domain
death agonist
Positive regulation of cysteine-type endopeptidase
activity involved in apoptotic process, regulation of
apoptotic process, extrinsic apoptotic signaling pathway
5.33 1.37 −0.60 9.79e-05
CASP4 Caspase 4 Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
74.8 23.66 −0.50 9.79e-05
CASP8 Caspase 8 Positive regulation of cysteine-type endopeptidase
activity involved in apoptotic process, regulation of
apoptotic process, extrinsic apoptotic signaling pathway
10.07 3.79 −0.42 9.79e-05
CYCS Cytochrome c, somatic Positive regulation of cysteine-type endopeptidase
activity involved in apoptotic process, negative regulation
of apoptotic process, regulation of apoptotic signaling
pathway
9.07 3.42 −0.42 9.79e-05
HSP90AA1 Heat shock protein 90
alpha family class A
member 1
Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
423.83 724.1 0.23 9.79e-05
MDM2 MDM2 proto-oncogene Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
15.7341 17.81 0.05 9.728e-02
PIK3CA Phosphatidylinositol-4,5-
bisphosphate 3-kinase
catalytic subunit alpha
Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
14.77 18.38 0.095 1.35e-03
PIK3CB Phosphatidylinositol-4,5-
bisphosphate 3-kinase
catalytic subunit beta
Regulation of apoptotic process, negative regulation of
apoptotic process, regulation of apoptotic signaling
pathway
3.33 5.60 0.22 9.79e-05
TNFRSF10B TNF receptor superfamily
member 10B
Positive regulation of cysteine-type endopeptidase
activity involved in apoptotic process, regulation of
apoptotic process, extrinsic apoptotic signaling pathway
63.87 38.70 −0.21 9.79e-05
TNFRSF11B TNF receptor superfamily
member 11B
Regulation of apoptotic process, regulation of apoptotic
signaling pathway
136.65 97.87 −0.14 9.79e-05
TNFRSF12A TNF receptor superfamily
member 12A
Regulation of apoptotic process, extrinsic apoptotic
signaling pathway
8.54 2.97 −0.47 9.07e-3
TNFRSF19 TNF receptor superfamily
member 12A
Regulation of apoptotic process, regulation of apoptotic
signaling pathway
25.96 9.10 −0.41 9.79e-05
Both the expression levels (Exp_Value) and the fold changes (FC) are expressed in log10. GO terms indicate their classification in different biological processes. Instead, the statistical
significance is indicated by False Discovery Rate (FDR), p-values ≤ 0.05 were considered statistically significant.
TABLE 3B | CBD modulated the apoptotic pathway in hGMSCs.
KEGG pathway Gene symbol FDR
Apoptosis APAF-1, AKT-1, BAX, BAD, BID, CYCS, CASP8, MDM2,
PIK3CA PIK3CB, TNFRSF10B
4.01e-17
The statistical significance is indicated by the False Discovery Rate (zFDR), p-values ≤ 0.05 were considered statistically significant.
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TABLE 4 | Mesenchymal markers differentially expressed between CTR-hGMSCs and CBD-hGMSCs.
Gene Description Go processes CBD-HGMSCS
Exp_Value
CBD-HGMSCS
Exp_Value
LOG10FC FDR Q_VALUE
CD13
(ANPEP)
Alanyl Aminopeptidase Single organismal cell-cell adhesion 114.68 120.90 0.02 4.36e-02
CD29
(ITGB1)
Integrin Subunit Beta 1 Cell adhesion
Cell-matrix adhesion
Single organismal cell-cell adhesion
511.60 666.69 0.11 9.79e-05
CD73
(NT5E)
Nt5e 5’-Nucleotidase Ecto Cell adhesion
Single organismal
cell-cell adhesion
314.08 360.84 0.06 9.79e-05
CD44 CD44 Molecule Cell adhesion
Cell-matrix adhesion
Single organismal cell-cell adhesion
306.34 295.16 −0.01 2.96e-02
CD90
(THY1)
Thy-1 Cell Surface Antigen Cell adhesion
Cell-matrix adhesion
Single organismal cell-cell adhesion
75.20 58.37 −0.11 9.79e-05
CD166
(ALCAM)
Activated Leukocyte Cell
Adhesion Molecule
Cell adhesion, single organismal cell-cell adhesion 58.64 53.18 −0.04 1.30e-02
The expression levels (Exp_Value) and the fold changes (FC) are expressed in log10. The statistical significance is indicated by the False Discovery Rate (FDR) value, p-values ≤ 0.05
were considered statistically significant.
TABLE 5 | CBD modulated the transcription of genes codifying for the antigenic repertoire of hGMSCs.
Gene Description Go processes CBD-HGMSCS
Exp_Value
CBD-HGMSCS
Exp_Value
LOG10FC FDR Q_VALUE
CD276 CD276 molecule Regulation of immune system process,
negative regulation of T cell proliferation,
negative regulation of inflammatory response
20.86 25.95 0.09 3.64e-4
CD47 CD47 molecule Regulation of immune system process,
leukocyte migration, integrin-mediated signaling pathway
13.11 16.64 0.10 2.77e-03
CD55 CD55 molecule Regulation of immune system process, Complement and coagulation
cascades
12.29 15.22 0.09 0.45e-02
CD40 CD40 molecule Immune system process, immune response, regulation of immune
system process
5.60 1.73 −0.50 9.79e-05
CD46 CD46 molecule Regulation of immune system process, T cell mediated immunity 54.35 42.68 −0.10 9.79e-05
CD59 CD59 molecule Immune system process, immune response, regulation of immune
system process
130.87 78.57 −0.22 9.79e-05
CD68 CD68 molecule Immune system process 134.37 116.70 −0.06 9.79e-05
CD81 CD81 molecule Regulation of immune system process, cell surface receptor signaling
pathway
404.95 270.42 −0.17 9.79e-05
CD82 CD82 molecule Cell surface receptor signaling pathway, regulation of immune system
process
24.53 15.88 −0.18 9.79e-05
CD99 CD99 molecule Immune system process, cell adhesion 685.80 638.84 −0.03 3.64e-03
Both the expression levels (Exp_Value) and the fold changes (FC) are expressed in log10. GO processes indicate their classification in different biological processes. Instead, the statistical
significance is indicated by False Discovery Rate (FDR), p-values ≤ 0.05 were considered statistically significant.
2010; Robinson et al., 2013), exerting immunosuppressive
properties.
Here, we have found that CBD treatment modified the
expression of genes codifying for surface antigens in hGMSCs.
Specifically, in CBD-hGMSCs we detected upregulated levels
of the well-known MSCs markers CD13, CD29, CD73, CD13,
CD29, CD73, involved in promoting MSCs adhesion and
migration. The overexpression of these markers has been
associated with improved MSCs therapeutic efficacy (Ode et al.,
2011; Rahman et al., 2014). Moreover, CBD treatment led to
the down-regulation of the MSCs markers CD44, CD90, CD166.
Interestingly, the downregulation of CD90, CD44, and CD166
has been linked to a more differentiated stem cell phenotype and
to a less tumorigenic potential (Moraes et al., 2016). Additionally,
we detected others surface markers involved the activation of the
immune system which expression was downregulated by CBD
such as CD109, CD151, CD40, CD46, CD59, CD68, CD81, CD82,
CD99. CD109, and CD151 are surface markers expressed by
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different cell types of the immune system (Zhang et al., 2015;
Seu et al., 2016). CD59 and CD99 and play a role in of T-cells
activation and migration (Kimberley et al., 2007), whereas CD68
promotes macrophage activation (Ji, 2012). CD40, CD46, CD81,
and CD82 are immune-costimulatory antigens which promote
the activation of different cells of the immune system (Levy
et al., 1998; Shibagaki et al., 1998; Zaffran et al., 2001; Elgueta
et al., 2009; Johnson and Ruffell, 2009; Saleh et al., 2013). In
parallel, CBD treatment led to the upregulation of antigens
which negatively regulate T cell activation via the disruption
of APC/T interactions as well as of antigen processing and
presentation, such as CD47, CD55, and CD276. In particular,
CD47 is expressed on most innate immune cells able to dampen
the inflammatory immune response (Latour et al., 2001). Instead,
CD276 (B7-H3) is a negative regulator of T cell proliferation,
as well as CD55 (DAF), a complement inhibitor protein that
suppresses T cells activation in vivo. Of note, transgenic
overexpression of humanDAF is a strategy to reduce the immune
rejection complement-mediated in xenotransplants (Liu et al.,
2005). Based on our results, we suggested that CBD treatment
by modifying the molecular immunophenotype of hGMSCs,
make them less immunogenic. A less immunogenic phenotype
can potentially prevent the allogenic immune responses without
requiring a systemic immune suppression in the host.
In conclusion, we found that CBD negatively regulated
the NALP3-inflammasome activation and cell death, via the
inhibition of apoptosis, through a CB1R-dependent. Moreover,
CBD treatment reduced the immunogenicity of hGMSCs.
In the present study, we will provide a new simple
and reproducible method for preconditioning hGMSCs with
CBD before transplantation. This method could represent an
interesting strategy for reducing the risk of immune reactions
following cell transplantation, and in parallel, for increasing their
survival and thus, their long-term therapeutic efficacy.
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